Cantargia AB (publ) (CANTA) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to Kantarga's presentation of the second quarter and first half year report for 2026. My name is Hilde Steininger, Chief Executive Officer at Kantarga, and I'm joined today by our Chief Financial Officer, Patrik Renblad. Today, I will take you through the operational and strategic progress during the quarter, including our clinical development plans and pipeline priorities. Patrick will then present the financial results for the second quarter and the first six months of 2026 before I return with a brief summary and we open up for questions. The central theme of today is how Kantarga continues to build on its leadership in IL-1 RAP antibody development with Nadenolamab as our lead oncology asset and with new opportunity emerging both in pancreatic cancer and hematologic malignancies. Next slide. Before we begin, I'd like to remind everybody that today's presentation contains forward-looking statements. These statements are subject to risk and uncertainties, and actual results may differ from those expressed or implied. We therefore encourage you to read through the Safe Harbor statement and the risk factor described in Contargia's public disclosures. Next slide, please. Today's presentation will be structured in three parts, as mentioned. I will first summarize the key events and then review our pipeline. Next slide. The second quarter was a pivotal one for Contargia with meaningful progress on both the financial and clinical development fronts. First, we strengthen our balance sheets. A rights issue combined with a loan facility from Fenja Capital delivered gross proceeds of 132 million Swedish kronors. This capital is earmarked for our key strategic clinical priorities of NABNULOMAB. Most notably, the planned combination study with the RA...